Navigation Links
Par Pharmaceutical To Acquire Anchen Pharmaceuticals
Date:8/24/2011

WOODCLIFF LAKE, N.J., Aug. 24, 2011 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) announced today that it entered into a definitive agreement to acquire Anchen Pharmaceuticals, a privately-held specialty pharmaceutical company focused on developing and commercializing extended release and niche generic products, for $410 million in cash.  The transaction is expected to be immediately accretive to non-GAAP earnings in 2011.

Anchen is a profitable, fully-integrated pharmaceutical company with five commercialized products, 27 ANDAs on file with the US FDA, five of which are believed to be first-to-file, and approximately 26 additional products in development.  Anchen anticipates launching 8-10 niche generic products over the next two years.  Headquartered in Irvine, California, Anchen has 218 employees and over 72,000 sq. ft. of expandable manufacturing and warehouse facilities with state-of-the-art equipment.

Patrick G. LePore, Chairman, CEO and President of Par Pharmaceutical Companies said, "This transaction accelerates the expansion of Par's research and development infrastructure and reinforces our strategy to provide long-term sustainable growth.  Anchen has an excellent development track record and robust product pipeline, which, when combined with Par's existing capabilities and pipeline, more than doubles our product opportunities."  Mr. LePore continued, "Anchen also shares Par's highly entrepreneurial culture and cost-efficient approach to product development, which should allow for a seamless integration."  

The Company intends to finance the transaction with cash on hand and a $350 million term loan.

The acquisition is subject to customary conditions and approvals.  Par expects to complete the transaction by the end of the year.

AdvisorsPar Pharmaceutical Companies was advised
'/>"/>

SOURCE Par Pharmaceutical Companies
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals to Present at the Stifel Nicolaus 2011 Healthcare Conference
2. Valeant Pharmaceuticals Files a Notice of Intention to Make a Normal Course Issuer Bid
3. KalVista Pharmaceuticals Launched With £8 Million in Series A Funding to Develop Novel Class of Drugs for Diabetic Macular Edema
4. Mainor Eglet Attorney, Robert Eglet, Calls Teva Pharmaceuticals Vice President Craig Lea to the Stand in Hepatitis C Trial
5. Endo Pharmaceuticals Announces Leadership Change at HealthTronics Subsidiary: Appoints Kelly Huang, Ph.D. New President
6. Spaulding Clinical Announces Strategic Partnership with Clinigene International, India for Providing Comprehensive Early Clinical Solutions to Pharmaceutical and Biotech Clients
7. Valeant Pharmaceuticals Completes Acquisition of Sanitas Group
8. CoLucid Pharmaceuticals Receives Clearance for Investigational New Drug (IND) Application for Lasmiditan for the Treatment of Acute Migraine
9. Valeant Pharmaceuticals Announces Resignation of Michael Van Every From Valeants Board of Directors
10. Endo Pharmaceuticals Announces Termination of Collaboration with Grunenthal for the Development of Axomadol
11. Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014  For Cloud Pharmaceuticals, Inc., ... and development, partnering is an integral part of ... design new drugs and identify early stage, preclinical, ... further their development. The company also partners with ... this business model, Cloud Pharmaceuticals will be participating ...
(Date:9/19/2014)... -- Merck (NYSE: MRK ), known as MSD outside ... , is teaming with celebrity chef and cookbook author Leticia ... an educational program encouraging Hispanics with type 2 diabetes to achieve ... to help reduce the risk of serious health problems. Hispanics in ... risk for developing type 2 diabetes than non-Hispanic white adults, and ...
(Date:9/19/2014)... 19, 2014 UBM Medica US announces that  ... community to help oncologists and other clinicians gain a ... use of targeted therapies and immunotherapies, discusses some of ... Every September, Blood Cancer Awareness ... awareness about blood cancers—helping to increase survival rates and ...
Breaking Medicine Technology:Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 3Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 5OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4
... Phase 1 Clinical Trial Results Disclosed, ... Inc., a,biopharmaceutical company developing "Best-in-Class" drugs for ... that the results,of multiple studies on its ... will be presented in eighteen presentations at ...
... CeNeRx BioPharma,Inc., a clinical stage company developing and ... system, today announced that,it has initiated a Phase ... for the treatment of major depressive disorder (MDD). ... novel class of drugs known as RIMAs,or reversible ...
Cached Medicine Technology:Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA 2Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA 3CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM) 2CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM) 3
(Date:9/21/2014)... NY (PRWEB) September 21, 2014 ... develops, implements and supports electronic medical records (EMR) ... benefited from federal healthcare legislation during the past ... do so during the five years to 2019. ... Clinical Health Act established Medicare and Medicaid incentives ...
(Date:9/21/2014)... Market Research Report on ... 2009-2019 is a professional and in-depth market ... 49562-28-9) industry. The report firstly reviews the ... its classification, application and manufacturing technology.The report ... of Fenofibrate (CAS 49562-28-9) listing their product ...
(Date:9/21/2014)... Chicago, IL (PRWEB) September 21, 2014 ... pain is so intense and difficult to resolve,” said ... and I can't think of a pain that is ... everyone who suffers from cluster headaches, or migraines, that ... based on the serotonin system,” he added. , Serotonin ...
(Date:9/21/2014)... 21, 2014 According to latest National ... birth rate since 1966 (10.5 births per 1,000 women in ... 40s has risen steadily by 2 percent per year. The ... women aged 50 and over) also rose, the first such ... more than nine times as many first births to women ...
(Date:9/20/2014)... September 21, 2014 Weight Destroyer ... by fitness expert Michael Wren that has already helped ... and reverse health conditions like high blood pressure, high ... Shane Michaels, prompting an investigative review. , “Weight ... tips upside down by showing people what is truly ...
Breaking Medicine News(10 mins):Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 4Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 2Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 3Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 4Health News:Homeostasis: Equinox Serotonin (5HT) Headache Stories ~ New on the Bryan William Brickner Blog 2Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 2Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 3Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 4Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 2Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 3
... , , BOTHELL, Wash., Aug. 10 ... (Nasdaq: CSCX ), a global leader in automated external ... announced that revenue for the second quarter ended June 30, 2009, was ... withhold $3 million in AED shipments during the quarter in accordance with ...
... WILMINGTON, Del., Aug. 10 Asthma expert Dr. Shailen Shah explains how to make living with ... , , What: Audio Podcast: Thank you for ... Asthma Success Podcast. This podcast will provide you with, ... asthma year round., ...
... , SALT LAKE CITY, Aug. 10 ... pioneer in cardiac assist technologies, announced today that it has appointed ... Brown brings over 16 years of experience to WorldHeart. , ... Research where he was Chief Financial Officer and Senior Vice President ...
... , Study Shows that Competitive ... Out-of-State Providers , ARLINGTON, Va., Aug. 10 ... this afternoon, unveiling a new economic study that exposes severe ... equipment and services. The bidding program is set to restart ...
... , , FRAMINGHAM, Mass. and SYDNEY, ... (ASX: HIN) today announced that it has entered into definitive agreements ... to sell approximately 2.5 million shares of its common stock in ... to purchase the shares at a purchase price of US$22.00 per ...
... transmission did not cause infection among caregivers in study ... study estimates that more than 12 percent of people ... infected with MRSA, or methicillin-resistant Staphylococcus aureus, and ... to others in their household. , The researchers, Dr. ...
Cached Medicine News:Health News:Cardiac Science Reports Q2 Revenue; Resumes AED Shipments 2Health News:Cardiac Science Reports Q2 Revenue; Resumes AED Shipments 3Health News:Cardiac Science Reports Q2 Revenue; Resumes AED Shipments 4Health News:Cardiac Science Reports Q2 Revenue; Resumes AED Shipments 5Health News:Cardiac Science Reports Q2 Revenue; Resumes AED Shipments 6Health News:Cardiac Science Reports Q2 Revenue; Resumes AED Shipments 7Health News:Cardiac Science Reports Q2 Revenue; Resumes AED Shipments 8Health News:Cardiac Science Reports Q2 Revenue; Resumes AED Shipments 9Health News:Cardiac Science Reports Q2 Revenue; Resumes AED Shipments 10Health News:Cardiac Science Reports Q2 Revenue; Resumes AED Shipments 11Health News:Cardiac Science Reports Q2 Revenue; Resumes AED Shipments 12Health News:Cardiac Science Reports Q2 Revenue; Resumes AED Shipments 13Health News:Cardiac Science Reports Q2 Revenue; Resumes AED Shipments 14Health News:Cardiac Science Reports Q2 Revenue; Resumes AED Shipments 15Health News:Cardiac Science Reports Q2 Revenue; Resumes AED Shipments 16Health News:Cardiac Science Reports Q2 Revenue; Resumes AED Shipments 17Health News:Cardiac Science Reports Q2 Revenue; Resumes AED Shipments 18Health News:Cardiac Science Reports Q2 Revenue; Resumes AED Shipments 19Health News:WorldHeart Appoints Morgan Brown as New Vice President of Finance and Chief Financial Officer 2Health News:New Economic Study Exposes Faults in Controversial Medicare Competitive Bidding Program Scheduled to Start this Fall 2Health News:New Economic Study Exposes Faults in Controversial Medicare Competitive Bidding Program Scheduled to Start this Fall 3Health News:New Economic Study Exposes Faults in Controversial Medicare Competitive Bidding Program Scheduled to Start this Fall 4Health News:HeartWare International, Inc. Announces US$55 Million Financing 2Health News:HeartWare International, Inc. Announces US$55 Million Financing 3Health News:Staph Infection May Follow People Home From Hospital 2
... Bio-Quant S. typhi rapid test is ... The test employs a conation of ... polyclonal antibody immobilized on the solid ... typhi,antigen associated Salmonella typhi (typhoid) infection ...
... InstaTest Mono is an immunochromatographic in ... associated with,infectious mononucleosis infection.,Infectious mononucleosis (IM) ... diagnosis of IM is based on ... infection, such as the,heterophile antibodies present ...
OneStep Midstream Urine hCG Pregnancy InstaTest is a test kit for the determination of hCG(Human Chorionic Gonadotropin) in urine specimens. This test kit is used to obtain a visual, qualitative resu...
... Myoglobin Insta Test is an ... test. It is designed for ... serum specimens. The presence of ... ng/mL or higher can be ...
Medicine Products: